Article Text

PDF

Management options
Anthracycline-induced cardiomyopathy
  1. N G Fisher,
  2. A J Marshall
  1. South West Cardiothoracic Unit, Derriford Hospital, Plymouth, Devon, UK

    Abstract

    Anthracycline cardiomyopathy is less frequently encountered nowadays, due to the well-recognised dose limitations and cardiac monitoring protocols used by chemotherapy centres. However, it is a condition that will persist due to the sensitivity of some patients to these drugs and the necessity for large doses to be used for certain individuals. We have demonstrated the benefit of angiotensin-converting enzyme inhibitor therapy and would consider introducing these compounds at the earliest opportunity. The use of probucol and vitamins as antioxidants capable of preventing the onset of cardiomyopathy in humans appears to require further investigation but may significantly reduce the incidence of this condition in the future.

    • anthracycline
    • cardiomyopathy

    Statistics from Altmetric.com

    Anthracycline therapy is known to be potentially cardiotoxic. The effects on the myocardium are predominantly dose-related and the incidence of this condition has declined in recent years, reflecting changing protocols. However, the problem still occurs up to 20 years after treatment1 and the case report in the box on the next page highlights this condition. The aetiology, epidemiology, detection, prevention and treatment of anthracycline cardiomyopathy is discussed.

    Anthracyclines

    Anthracyclines (doxorubicin, daunorubicin, epirubicin, aclarubicin and idarubicin) are extremely important in the treatment of lymphomas, breast cancer and soft tissue sarcomas. They were discovered as fermentation products of Streptococcus verticillus and exert their cytotoxic activity by their ability to cause DNA fragmentation.

    Mechanism of cardiotoxicity

    The exact mechanism of cardiac toxicity is not known. However the most accepted mechanism is that of free radical formation and interference with the mitochondrial electron transport chain.2 The heart is rich in mitochondria and has a relatively poor ability to rid itself of free radicals due to its reliance on the glutathione–glutathione peroxidase cycle3; it is therefore particularly vulnerable to free radical attack.

    Epidemiology of cardiotoxicity

    The incidence of congestive cardiac failure (CCF) with epirubicin is 0.7%, with a median cumulative dose of 660 mg/m2 4 5Doxorubicin is more cardiotoxic than epirubicin and the incidence of CCF ranges from 3–4% with a cumulative dose of 450 mg/m2to 18% with a cumulative dose of 700 mg/m2.6-8 CCF usually develops within 9–192 days, with a peak incidence 1–3 months after the last dose.9 Despite these relatively low figures of CCF the incidence of subclinical myocardial damage is much higher, even at lower doses.10-12 It is difficult to predict which patients are likely to develop CCF and long-term follow-up of all patients is necessary, as the condition has been shown to manifest up to 20 years after treatment.1

    Formerly, once patients had developed CCF the usual outcome was considered to be fatal in the majority of patients.8Subsequent studies have produced more encouraging results, however, indicating that improvement can be seen in up to 80% of patients.13 In addition, there appears to be continued improvement seen when studies have followed patients in the subsequent four years.12 These figures compare favourably with idiopathic dilated cardiomyopathy in which progressive deterioration is usually seen, with 75% of patients dying within 5 years.14

    Detection of cardiotoxicity

    Initially an endocardial biopsy was required for detection of anthracycline-induced cardiomyopathy15 but recent studies using radioactive monoclonal antibodies against cardiac muscle, as well as the MIBG scan, have been able to provide virtually the same degree of information without requiring such invasive investigations.16 17 However, the use of both of these investigations in daily practice is frequently not feasible, and the ejection fraction tends to be used as a baseline measure of myocardial function prior to treatment, and for early detection of cardiac damage post-treatment. The optimal investigation for measuring the left ventricular ejection fraction (LVEF) is the subject of some debate, with doctors divided between nuclear angiography and echocardiography. Two techniques using echocardiography are commonly used, the cubed technique with M-mode and secondly that produced from the use of Simpson's Rule. The cubed technique is the simplest method for measuring ejection fraction and assumes that the left ventricle is an ellipsoid, which is unfortunately frequently not the case in patients with cardiomyopathy. The volume is therefore calculated by cubing the diameter, and the ejection fraction can be calculated by subtracting the systolic volume from the diastolic volume. The computer-based calculation based on Simpson's Rule goes some way to reducing these errors. This assumes that the left ventricular volume is the sum of the volumes of a set of adjacent discs of varying depth and cross-sectional area. Several authors have found that the two correlate quite closely, especially when the echocardiologists used Simpson's technique.17-19 Also, despite small differences, they show a linear correlation with changing LVEF. The most important factor, regardless of the method chosen, is the consistency of the measuring technique and every effort should be made to ensure that operators and equipment are the same throughout a patient's review period. Particularly important in this patient group is the presence of anaemia, as it is not uncommon for an anaemic patient to drop his LVEF more than 10% when the anaemia is corrected.20 When these criteria are applied, changes in results due to operator error are kept to a minimum.

    Prevention of cardiomyopathy

    REDUCTION OF CUMULATIVE ANTHRACYCLINE DOSE

    There is little doubt that cardiac damage is related to total cumulative dose, with those receiving more than 400 mg/m2being at significant risk.21 There is also evidence of a cumulative affect with other chemotherapeutic agents, leading to severe and fatal cardiotoxicity even at doses below 400 mg/m2.22 Mediastinal irradiation appears to lower the cumulative dose necessary for the development of cardiotoxicity, and hypertension also appears to potentiate the development of adriamycin cardiotoxicity at lower doses.23Children are especially susceptible with those under 4 years of age being in greatest danger.24 There is also evidence that females are more likely to develop late cardiotoxic events25 and patients over 60 years have been found to have a four-fold greater risk of developing CCF than patients of 39 years.21

    IRON CHELATORS AND ANTI-OXIDANTS

    The iron chelator ICRF-187 has been shown to reduce oxygen free radical production and reduce the severity of cardiomyopathy in dogs but is associated with an increase in haematological toxicity.26 Vitamins C and E are powerful anti-oxidants and in mice vitamin E offered some early protection against the development of acute cardiotoxicity, although it did not appear to reduce long-term mortality.27 28 Vitamin C has significantly increased the lives of animals treated with adriamycin29 and there is likely to be a synergistic benefit when vitamins E and C are given together. Further studies with these vitamins are awaited.

    The lipid-lowering drug probucol has now been replaced in this role by the more effective HMG Co-A reductase inhibitors. However, it also has anti-oxidant properties, and in rats it appears to offer complete protection against adriamycin-induced cardiomyopathy without interfering with the drug's anti-tumour properties.30 No trials in humans have to date been reported.

    SERIAL MONITORING OF EJECTION FRACTION

    Schwartz et al have demonstrated that serial monitoring of resting LVEF using serial radionuclide angiocardiography significantly reduces the incidence of clinical congestive cardiac failure when a few simple rules are applied.13 In their study, 1487 patients receiving doxorubicin chemotherapy were divided into two groups according to whether their LVEF was above or below 50%. Patients with LVEF below 30% were considered unfit for doxorubicin chemotherapy. The two groups were then treated as shown in box FB2. Chemotherapy was stopped when LVEF fell >10% or reached 30%.

    Figure 2

    M-Mode echocardiograms taken before (A) and after (B) chemotherapy

    Figure FB1
    Figure FB2

    There is obviously a need for continued echocardiographic observation in order to detect those patients who go on to develop late onset cardiomyopathy. There are no firm guidelines on the timings of this follow-up, but with the knowledge that the majority of complications will occur in the first year, and are more frequent in those with abnormal echocardiogram results at the end of treatment,31a suitable plan can be tailored to individual patients. The time interval between each review should also be adjusted with the knowledge that once the LVEF starts to fall it can do so precipitously.32

    treatment of cardiomyopathy

    The traditional approach to left ventricular failure has been frusemide and digoxin, with the latter being more popular in the US. A recent study has shown that the addition of enalapril or ramipril to this combination in patients with epirubicin-induced cardiomyopathy resulted in an increase of LVEF from 18–30% to near normal.33 Research is currently investigating the benefit of angiotensin-converting enzyme (ACE) inhibitors immediately after cessation of chemotherapy. The use of ACE inhibitors in conjunction with chemotherapy is yet to be addressed.

    Another promising treatment is the selective beta-1 antagonist metoprolol. Okamoto et al achieved an increase in LVEF from 33–50% in a patient with daunorubicin-induced cardiomyopathy by titrating the dose from 5 to 40 mg/day over a 2-month period.34

    If the patient recovers from the malignancy for which the chemotherapy is being given, heart transplantation is a possible option and there are well-documented reports of children and young adults remaining well and in continued remission at least 3 years after transplantation.35 Transplantation centres will normally expect the patient to have been disease free for at least one year36 and the importance of improved medical therapy remains, as the majority of patients who are going to develop cardiomyopathy will have done so well within this time scale.

    Acknowledgments

    We are grateful to Dr Prentice, Consultant Haematologist, for allowing us to describe his patient in this review.

    References

    View Abstract

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.